Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 8/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 8/20 | 0.53 |
| ▸ | TMEM97 | Q5BJF2 | 4/20 | 0.53 |
| ▸ | DPP4 | P27487 | 1/20 | 0.50 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.49 |
| ▸ | DRD3 | P35462 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.45 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24493085 | 0.90 | GPR119 (0.47) | DRD4SIGMAR1TMEM97DPP4GPR119 | |
| SCHEMBL13590834 | 0.87 | GPR119 (0.52) | GPR119TP53DDB1CRBN | |
| SCHEMBL4469145 | 0.87 | DRD4 (0.53) | DRD4SIGMAR1TMEM97 | |
| SCHEMBL29735456 | 0.85 | GPR119 (0.59) | DRD4GPR119TP53 | |
| SCHEMBL18280020 | 0.85 | GPR119 (0.59) | DRD4GPR119TP53 | |
| SCHEMBL18280030 | 0.83 | DPP4 (0.52) | DPP4GPR119TP53 | |
| SCHEMBL1575601 | 0.83 | GPR119 (0.52) | DPP4GPR119 | |
| SCHEMBL9483382 | 0.83 | GPR119 (0.58) | GPR119TP53DDB1CRBN | |
| SCHEMBL16600153 | 0.83 | DRD4 (0.55) | DRD4SIGMAR1TMEM97DRD3 | |
| SCHEMBL5534867 | 0.82 | CARM1 (0.55) | GPR119DDB1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9850203-B2 | Autotaxin inhibitor compounds | PHARMAKEA, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| US-9850203-B2 | Autotaxin inhibitor compounds | PHARMAKEA, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| US-20160214935-A1 | AUTOTAXIN INHIBITOR COMPOUNDS | DF 2024 IP ACQUISITION, LLC | 2016-07-28 | — | — | US | disclosed |
| US-20160214935-A1 | AUTOTAXIN INHIBITOR COMPOUNDS | DF 2024 IP ACQUISITION, LLC | 2016-07-28 | — | — | US | disclosed |
| WO-2015048301-A1 | AUTOTAXIN INHIBITOR COMPOUNDS | PHARMAKEA, INC. (US) | 2015-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160214935-A1 | AUTOTAXIN INHIBITOR COMPOUNDS | ENPP2, SERPINB1, SERPINE1 | DRD4 4856/4885SIGMAR1 4804/4885TMEM97 4569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.